SOCIAL CONTENT BANKThirty posts across LinkedIn, Instagram and TikTok, written for the partner buyer and checked against the seven hard rules.

A royalty is quoted as a percentage, which makes it feel like a rounding error. It is not a percentage of profit. It is a percentage of gross.

That distinction is the whole game.

Gross does not care what you paid for product, staff, rent, or ads. It gets paid before you do, and it keeps getting paid.

Two things people miss when they model it:

1. The royalty is senior to you. In a soft month, you still owe it.

2. It scales with your effort, not theirs. In year one they built something for you. In year six you built it, and the percentage is unchanged.

None of that makes franchising wrong. A good franchise sells a proven system and a brand that already means something before you open the door. And a Franchise Disclosure Document makes the terms legible in a way most private license deals never do. That is a genuine advantage of the franchise structure, and it cuts against me.

But price the royalty honestly: it is a permanent partner with a first claim on revenue, whom you cannot fire.

Atlas Metabolic is a license, not a franchise. One-time license fee, 0% of revenue, no ongoing partner fees.

That choice carries its own trade-off, and I would rather say it out loud than let you find it later: we have no FDD, so the diligence a disclosure document would have done for you is yours to do.

If you want the mechanics rather than the slogan, we wrote up how a gross royalty actually compounds at atlasmetabolic.com/learn/fdd-item-6-gross-royalty-explained, and the structural difference between a franchise and a license at /learn/franchise-vs-license.

#franchising #businessownership #licensing #duediligence

Compliance: No fee figure, no royalty percentage invented, no income or savings claim. Does not assert that a license costs less or earns more than a franchise, only that the claims sit at different points in the revenue stack. Credits the FDD as a franchise advantage, per the 'no-FDD is our disclosed weakness' doctrine. Lexicon: partner, license fee, Atlas Metabolic. No competitor named.

You can own a metabolic wellness business. In much of the country you cannot own the medicine. Those are two different sentences and most first-time buyers hear only one.

The corporate practice of medicine doctrine is a body of state-level rules barring unlicensed persons and corporations from owning or controlling a medical practice, or employing physicians for clinical care. Its stated purpose is to keep medical judgment independent of business pressure (Milbank Memorial Fund issue brief, April 28, 2025 — VERIFIED).

The rules vary by state, so I will not give you a count. Anyone who quotes you a tidy national number is repeating a figure that the primary literature declines to state.

The standard structural response is separation: a clinician-owned professional corporation for clinical care, and a management services organisation for the non-clinical side. Enforcement risk turns on how much control the MSO exercises over clinical operations and professional judgment (Milbank, same brief — VERIFIED).

And the direction of travel in 2025 was tightening, not loosening: Massachusetts enacted MSO ownership transparency requirements, while Oregon, Washington and California saw CPOM-strengthening bills introduced (VERIFIED).

So when someone sells you a 'clinic in a box', the question is not whether they have a structure. It is which side of the line each function sits on, and who signs the clinical decisions.

Atlas Metabolic provides no medical services and employs no clinicians. Clinical care is delivered by a separately licensed medical entity. That is a hard boundary, not a preference.

This is general information, not legal advice, and it is not a statement of what your state permits. Take the structure to your own healthcare counsel and have them mark it up. Background reading: atlasmetabolic.com/learn/compliance-basics-for-wellness-businesses and /learn/independent-clinic-sovereign-ownership.

#healthcarecompliance #CPOM #healthcarebusiness #MSO

Compliance: Explicitly framed as what to verify with your own counsel in your state, never as a statement of what the law permits. Declines to give a CPOM state count, per the DO NOT USE flag on that figure. Restates that Atlas provides no medical services and employs no clinicians, with clinical care attributed to a separately licensed medical entity. No price, no income claim, no fabricated person.

Cash-pay demand in metabolic health is usually explained as a fad. It is closer to the opposite: a large part of it is written into statute.

Three pieces of the coverage picture, all public:

Medicare Part D has been barred by statute from covering drugs used for weight loss since the program was created under the 2003 Medicare Modernization Act. The temporary Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 at a $50 monthly copay, and those copays do not count toward Part D deductibles or out-of-pocket maximums. The BALANCE model started for Medicaid in May 2026 and was delayed indefinitely for Part D after plan participation fell short of an 80% enrollment threshold. Participation is voluntary (KFF — VERIFIED).

Employer coverage of GLP-1s used primarily for weight loss splits sharply by employer size: 16% of firms with 200 to 999 workers, 30% at 1,000 to 4,999, 43% at 5,000-plus (KFF 2025 Employer Health Benefits Survey, 1,862 firms — VERIFIED).

And among people already using these drugs, 56% reported difficulty affording them, 27% had insurance but paid the entire cost themselves, and 14% stopped because of cost (KFF, fielded Oct 27 to Nov 2, 2025 — VERIFIED).

My read: the cash-pay lane here is produced by a statutory exclusion addressed only through temporary voluntary programs, plus majority non-coverage among mid-sized employers. That is a structural mechanism, not a supply blip. Label it INFERENCE — it is my reasoning, not a published finding.

One thing it is not: a forecast of anyone's business. Coverage data describes the landscape. It says nothing about what any operator takes in.

If you are evaluating this category, read the coverage data before the pitch decks. Our overview of the market structure is at atlasmetabolic.com/learn/metabolic-wellness-market-overview, and the cash-pay mechanics at /learn/cash-pay-metabolic-health-program-structure.

#healthcare #GLP1 #healthpolicy #cashpay

Compliance: All figures drawn verbatim from the VERIFIED shared fact base with publisher attribution and field dates. The structural read is explicitly labelled INFERENCE and never upgraded. Contains an express statement that coverage data is not a forecast of any operator's results, blocking the market-data-to-earnings bridge. No price, no competitor, no fabricated person.

Here is the question almost nobody asks on a licensing call, and it is the one I would ask first: if I stop paying you tomorrow, what do I still own?

Buyers interrogate the deliverables list for an hour and never test the exit.

Go down this list and make them answer in writing, in the agreement, not in the deck:

The brand name and the marks. Yours, or licensed to you and revocable?

The domain and the website. Whose registrar account holds it?

The member list and the contact data. Can you export it, in full, in a usable format, on any day you choose?

The phone number. It is the single most-missed asset in the entire category.

The ad accounts and the pixel history. Rebuilding audience data is not the same as owning it.

The supplier relationships. Do you contract directly, or only through them?

And the post-termination clause itself: what survives, what reverts, what you are barred from doing next.

If the answer to most of those is 'ours', you did not buy a business. You rented a storefront and paid for the fixtures.

Ask us the same question. Atlas Metabolic's position is that the brand and the member relationships belong to the partner, and I want the contract language quoted here rather than my intent: Ask Atlas to put this in writing: exact post-termination brand, domain, member-data and phone-number ownership clauses as written in the current Atlas license agreement, quoted verbatim.

Steal the list. Use it on every operator you evaluate, including us. Longer version at atlasmetabolic.com/learn/due-diligence-checklist, and the ownership argument at /learn/owning-your-brand.

#duediligence #businessownership #licensing #entrepreneurship

Compliance: Unset contract specifics are written as a CONFIG token rather than asserted, per the never-invent-a-business-fact rule. Invites the same scrutiny of Atlas that it recommends applying elsewhere. No price, no income claim, no competitor named, no fabricated person or quote. Lexicon: partner, member.

A list of things Atlas Metabolic does not have. You will hear the rest from our marketing; you should hear this part from me.

We do not have a Franchise Disclosure Document. We are a license, not a franchise, so no regulator compels us to hand you a standardised disclosure. That is a real gap in your favour of caution, not ours, and it means the diligence burden sits with you. We will hand you material to make that work easier, but I am not going to pretend the gap is not there.

We do not have a long public roster of partner results to point at. When we have consented, verifiable proof, it goes here: — to be filled only with a named, real partner who has signed a written consent to be quoted, describing what was built and over what period, with no figures attached.

We do not have published member outcome data, and we make no efficacy claims about any medication or supplement.

We will never have income claims. Not a range, not a projection, not a labelled hypothetical. A company with no FDD publishing earnings numbers is not being generous with you; it is the red flag itself.

We do not have exclusive geography to sell. Franchises sell protected territory. We do not, and I would rather you buy on the strength of the build than on a map.

We do not provide medical services and employ no clinicians. Clinical care is delivered by a separately licensed medical entity.

And for the record: Ask Atlas to put this in writing: number of completed builds to date and the date of the earliest one, stated plainly.

If that list makes you less interested, it did its job. If it makes you more interested, the fit call is where the specifics live.

#transparency #founders #businessownership #duediligence

Compliance: Uses with an explicit specification of the real, consented proof that must fill it, rather than any invented partner. Uses CONFIG for the unset build count. Affirms the permanent no-income-claims position and the no-efficacy-claims position. 'Territory' appears only in contrast with what franchises do, per the lexicon exception. No price, no competitor named.

If a business model you are being shown depends on compounded GLP-1s, open the April 30 docket before you open the contract.

The timeline is public and it is not ambiguous.

FDA removed tirzepatide from the shortage list in December 2024, with compounders expected to cease by March 2025. FDA declared the injectable semaglutide shortage resolved on February 21, 2025; enforcement discretion ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities (VERIFIED).

Then on April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, finding no clinical need and expressly rejecting affordability and insurance access as constituting clinical need. The comment period was extended, with comments due July 30, 2026 (Federal Register docket notice, June 26, 2026 — VERIFIED).

Meanwhile FDA has said plainly that a compounded product with the same active ingredient is not the drug FDA reviewed and approved, and that it does not evaluate specific compounded products for safety, effectiveness, manufacturing quality or consistency. It has logged hundreds of adverse event reports tied to compounded semaglutide and tirzepatide, and issued more than 50 warning letters in September 2025 over statements it deemed false or misleading (VERIFIED).

IQVIA reported in October 2025 that compounded prescribing did not abate after delisting, and that over 80% of compounded prescriptions include supplemental ingredients (VERIFIED).

So the demand persisted. The question for a buyer is not demand. It is durability: what happens to the program you just licensed if that pathway narrows further?

Ask it. In writing. Of anyone, including us.

Clinical and formulary decisions are not ours to make; they belong to a separately licensed medical entity, and Atlas makes no efficacy claims about any product. Structural background at atlasmetabolic.com/learn/how-supplement-supply-chains-work and /learn/glp1-clinic-business-model-margins.

#FDA #GLP1 #compounding #riskmanagement

Compliance: Every regulatory fact is VERIFIED in the shared fact base and presented with its dates, per the instruction that the 503B proposal must carry them. No efficacy claim, no guarantee, no medical advice; clinical authority attributed to a separately licensed medical entity. Presents a risk to Atlas's own category rather than an attack on any named competitor. No price, no income claim.

'Turnkey' is not a specification. It is a mood. Here is how to force it to become a specification before you sign anything.

Make them produce a line-item list where every row has three columns: the deliverable, the named owner, and the date it exists.

Then apply one test to each row. On day one after the build, does this thing run, or does it arrive as a template I have to finish?

Both answers can be acceptable. A brand kit is inherently a template and that is fine. A telehealth stack that is 'a template' is not a stack.

The rows that are most often fudged:

Ordering and fulfilment. Live and tested, or a vendor introduction?

The clinical relationship. Contracted with a separately licensed medical entity, or a list of people to go call?

Multi-state licensure. Whose job, whose cost, whose timeline?

Member-facing technology. Deployed under your brand, or a demo you get a login to?

Marketing. Assets and playbooks handed over, or campaigns actually running?

Support after the build. What is included by name, for how long, and what becomes billable?

If the answer to any of these is a paragraph rather than a row, that is the answer.

We hold ourselves to the same table. What Atlas Metabolic delivers in a build is written as a list, not as an adjective — and where it is a template rather than a running system, we say so in the row.

Bring the three-column table to every call you take in this category. Ours included. More at atlasmetabolic.com/learn/what-turnkey-actually-means and /learn/how-to-start-a-metabolic-reset-clinic.

#duediligence #operations #businessownership #healthcarebusiness

Compliance: No deliverable is asserted as existing beyond what the offer summary states; the post argues for auditing rather than listing unverified inclusions. Lexicon observed: build (never onboarding or deployment), member, partner, separately licensed medical entity. No price, no income claim, no competitor named, no fabricated person.

People keep asking why our license fee is not on the website. The honest answer is not scarcity marketing, and it is not what you think.

A number with no scope attached is noise.

If I publish a figure, you will do what any rational buyer does: put it next to somebody else's headline figure and treat the smaller one as better. That comparison is structurally broken, because those two numbers are not the same kind of number.

Ours is one-time, with 0% of revenue and no ongoing partner fees. A franchise headline fee sits at the front of a royalty stream that runs for the life of the agreement. You cannot compare the front numbers without modelling the stream, and a website cannot model the stream for you.

So the fee goes where the scope goes: on the fit call, alongside the full deliverable list, the exclusions, and the honest account of what you still have to fund yourself. That last part is the reason. A fee quoted without the exclusions is a half-truth, and half-truths in this category are how people get hurt.

Where the number belongs, we write it plainly and completely: The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own..

What I will publish, permanently: no revenue share, no ongoing partner fees, and no earnings figures of any kind — not now, not later, not as a labelled hypothetical.

If a company will tell you what you are going to make before it will tell you what you are going to pay, you have learned everything you need to know about the company.

Compare the structures, not the headlines: atlasmetabolic.com/learn/what-a-royalty-really-costs and /learn/medical-wellness-franchise-cost-comparison.

#pricing #licensing #franchising #businessownership

Compliance: Contains no figure, no range and no directional hint about magnitude; explicitly declines to claim the license fee is cheaper than any alternative. Uses the literal The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. token where a price would sit. Reaffirms the permanent ban on earnings figures including labelled hypotheticals. No competitor named. Lexicon: license fee, partner.

Going telehealth-first does not make a metabolic business cheaper. It moves the cost onto different lines. People discover the new lines after they have committed.

What a telehealth-first or hybrid model avoids is legible: build-out, renovation, clinical equipment.

What it adds is less legible, and the two do not net out to a number I can hand you.

Multi-state licensure. The practice of medicine is generally deemed to occur where the patient is located, so a clinician typically must be licensed in that patient's state. The Interstate Medical Licensure Compact covered up to 43 member states as of March 2026, which is a streamlined pathway, not an exemption (VERIFIED).

Controlled-substance registration where applicable. The DEA practitioner registration fee is $888 per three-year term under 21 CFR 1301.13 (VERIFIED). Small line, easy to forget, hard to skip.

Liability. Medical liability premiums rose for a seventh consecutive year, with the share of premiums increasing year over year climbing from 13.7% in 2018 to nearly 40% in 2025, the highest since 2005 (AMA Policy Research Perspectives, May 4, 2026, using Medical Liability Monitor data — VERIFIED). Premiums are intensely local: the reported 2025 internal medicine manual premium in Miami-Dade County was $59,736, which is a high-cost outlier and should never be read as typical.

Technology, which becomes a recurring line rather than a one-time one.

Commonly repeated first-year startup ranges circulate widely, but I could not trace them to any authoritative survey, so treat them as INFERENCE and price your own market instead.

These are cost lines only. Nothing here implies what any business takes in.

Model the composition before you pick the model: atlasmetabolic.com/learn/telehealth-vs-in-clinic-metabolic-care and /learn/clinic-vs-digital-model.

#telehealth #healthcarebusiness #operations #startupcosts

Compliance: Cost figures only, drawn from VERIFIED sources with attribution; the Miami-Dade premium is expressly presented as a high-cost outlier per the fact base. Startup ranges labelled INFERENCE and not relied on. Closes with an explicit statement that no revenue is implied, blocking any cost-to-margin derivation. MGMA not cited. No price, no competitor, no fabricated person.

A $95 billion market is not a business plan. It is a weather report. And the moment someone slides from the market number to your number, the conversation has stopped being analysis.

Look at how far apart the credible forecasts sit.

Goldman Sachs Research puts the global anti-obesity drug market at roughly $95 billion by 2030, revised down from roughly $130 billion (VERIFIED). Morgan Stanley Research projects global GLP-1 sales across diabetes and obesity at roughly $190 billion by 2035, more than double 2025 levels (VERIFIED). Grand View Research puts the narrower GLP-1 weight-loss segment at roughly $48.8 billion by 2030 on an 18.5% CAGR (VERIFIED).

Those are not contradictions. The gap is definitional — different scopes, different horizons. But notice which one a pitch deck reaches for, and notice that Goldman's number went down, not up.

Underneath the forecasts, the demand side is steadier than the projections: US adult obesity prevalence was 40.3% and severe obesity 9.4% in August 2021 to August 2023, and 72.4% of adults aged 20-plus had overweight including obesity (CDC/NCHS — VERIFIED). Age-adjusted obesity prevalence did not change significantly from 2013-2014 through that period, while severe obesity rose. And 12% of US adults are currently using a GLP-1, up six points since May 2024 (KFF, fielded Oct 27 to Nov 2, 2025 — VERIFIED).

Here is the only honest use of all of that: it establishes that the demand is structural rather than faddish. It does not tell you your share, your revenue, or your outcome, and no one can honestly derive those for you.

That is the tell to listen for. If a licensor moves from category size to what you will make in the same breath, they have just made an earnings claim with no basis. Walk.

Read the forecasts side by side rather than one at a time: atlasmetabolic.com/learn/metabolic-wellness-market-overview and /learn/evaluating-business-opportunities-questions.

#marketresearch #GLP1 #duediligence #investing

Compliance: Uses only VERIFIED market and prevalence figures with publisher attribution, and deliberately leads with the downward Goldman revision per the fact base guidance. Omits the unattributable Morgan Stanley penetration detail and every DO NOT USE figure. Explicitly refuses the market-size-to-personal-earnings bridge and names that bridge as a warning sign. No price, no competitor, no fabricated person.

Slide 1: "0% of your revenue." Read that again, then read what you're being asked to sign.

CAROUSEL SCRIPT (7 slides)

Slide 1 — 0% of your revenue.
Slide 2 — A royalty is not a fee. It's a permanent claim on every dollar that moves through your business.
Slide 3 — Fixed cost: you pay it once, you're done. Percentage cost: you pay it in year one, year five, and on the day you sell.
Slide 4 — The uncomfortable part is that a royalty scales with your effort. Work harder, pay more. That's the design, not a bug.
Slide 5 — Atlas Metabolic licenses the whole build — telehealth stack, ordering system, member AI coaching, brand kit, operational playbooks — for a one-time license fee. 0% of revenue. No ongoing partner fees.
Slide 6 — What that means for the exit: the buyer of your business isn't inheriting somebody else's percentage.
Slide 7 — We do not publish the license fee. It belongs on the fit call, with the person who has actually read the agreement. The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own.

We wrote the long version: what a royalty really costs, and how a gross royalty actually compounds, both in the library.

Link in bio → /learn/what-a-royalty-really-costs and /learn/fdd-item-6-gross-royalty-explained. If you want the fee, book the fit call.

#businessownership #licensingmodel #healthcarebusiness #cashpaypractice #entrepreneurship #dealstructure #businessduediligence

Compliance: No fee figure (The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. token used). The rising/flat line on slide 3 must carry NO numbers or axis values — it illustrates cost structure only; adding any dollar or revenue scale converts it into an earnings claim. 'License fee', 'partner', 'build', 'member' per lexicon. No competitor named. Word 'territory' not used. Designer must not add a P&L, payback timeline or 'save X' callout.

72.4%.

72.4% of US adults aged 20 and over had overweight, including obesity, in the August 2021–August 2023 measurement period. Adult obesity prevalence was 40.3%; severe obesity 9.4%. Highest in the 40–59 age band at 46.4%.

Source: CDC / National Center for Health Statistics, Data Brief 508 and CDC FastStats (NHANES).

One more line from the same data that people skip: age-adjusted obesity prevalence did not change significantly from 2013–2014 through August 2021–August 2023. Severe obesity rose over that same stretch.

That is a market description. It is not a forecast, and it is not a statement about what any operator will do — we don't make those, and you should be suspicious of anyone who does.

If you want the structural read on why this category runs cash-pay, start with how a cash-pay program is actually structured in the library.

Link in bio → /learn/cash-pay-metabolic-health-program-structure and /learn/metabolic-wellness-market-overview.

#marketdata #healthcarebusiness #cdc #cashpaypractice #businessopportunity #duediligence #publichealthdata

Compliance: VERIFIED figures, CDC/NCHS Data Brief 508 and CDC FastStats. Source rendered on-image so the stat cannot travel without attribution. Explicit non-bridge sentence included to block the market-data→earnings inference. No people depicted — avoids both fabricated-human and transformation-content problems. No medication imagery.

27% of them had insurance and paid the entire cost themselves.

KFF's health tracking poll, fielded October 27 – November 2, 2025:

· 18% of US adults have ever used a GLP-1 drug; 12% are currently using one — up six points since May 2024.
· Among users, 56% reported difficulty affording it. 25% said 'very difficult.'
· 27% had insurance but paid the entire cost themselves.
· 14% stopped because of cost.

Source: KFF Health Tracking Poll, November 2025.

That fourth-from-last line is the one that matters structurally. A person with a card in their wallet, paying cash anyway, is not a temporary market condition — it is what the coverage landscape currently produces.

We're describing coverage, not predicting demand and not describing anyone's results.

The deeper version — why the cash-pay structure exists and how a program gets built around it — is in the library.

Link in bio → /learn/cash-pay-metabolic-health-program-structure and /learn/glp1-clinic-business-model-margins.

#kff #healthcaredata #cashpay #healthcarebusiness #marketresearch #businessowners #duediligence

Compliance: All four figures VERIFIED from KFF (Oct 27–Nov 2 2025 field dates stated). Field date on-image because the caption may be truncated. Explicit disclaimer that this characterises coverage, not demand volume or operator results — required because affordability data is the most tempting bridge to an earnings claim. No efficacy statement about any drug; the post describes payment behaviour only.

Slide 1: Medicare has been barred from covering weight-loss drugs since 2003. Not by policy. By statute.

CAROUSEL SCRIPT (6 slides)

Slide 1 — Since 2003, Medicare Part D has been prohibited by statute from covering drugs used for weight loss. That's the Medicare Modernization Act, not a plan decision.
Slide 2 — The workarounds are temporary and voluntary. The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 at a $50 monthly copay — and those copays do not count toward Part D deductibles or out-of-pocket maximums.
Slide 3 — The BALANCE model started for Medicaid in May 2026 and was delayed indefinitely for Medicare Part D after plan participation fell short of an 80% enrollment threshold. State and plan participation is voluntary.
Slide 4 — Employer side, KFF 2025 Employer Health Benefits Survey (1,862 firms, fielded Jan–Jul 2025): coverage of GLP-1 agonists used primarily for weight loss runs 16% at firms with 200–999 workers, 30% at 1,000–4,999, 43% at 5,000+.
Slide 5 — Among the largest covering firms, 59% saw utilisation above projection and 66% reported significant prescription drug spending impact. Coverage that expensive is coverage under pressure.
Slide 6 — Read it as structure, not as opportunity-hype: this is a description of who pays, not a forecast and not a claim about what any business will do.

Sources: KFF Medicare policy analysis; KFF 2025 Employer Health Benefits Survey.

Link in bio → /learn/metabolic-wellness-market-overview and /learn/clinic-vs-digital-model.

#healthpolicy #medicare #employerbenefits #healthcarebusiness #marketstructure #kff #businessresearch

Compliance: All figures VERIFIED (KFF Medicare analysis; KFF EHBS 2025 with sample size and field window stated). Dates carried on every time-bound item, per the fact base. No projection of coverage trends beyond what KFF states — the 28%→43% change is available but the bar chart must not be drawn as a forward trend. Slide 6 blocks the coverage→earnings bridge. No legal advice: statute is described, not interpreted for the reader's situation.

'Turnkey' is the most abused word in this category. Here's ours, itemised.

A build is a delivery event, not a welcome email.

What gets handed over:
· The telehealth stack, configured — not a login to somebody's demo.
· The ordering system, wired end to end.
· Member AI coaching, live in your brand.
· The brand kit: name treatment, palette, type, asset library, site.
· Operational playbooks — the boring documents that decide whether week six works.

What Atlas is not: Atlas provides no medical services and employs no clinicians. Clinical care sits with a separately licensed medical entity. That separation is deliberate, it's structural, and any partner should confirm how it applies in their state with their own counsel.

What you still own after the build: the brand, the member relationships, the business. We take a one-time license fee and 0% of revenue, so there is nothing for us to keep collecting.

If you want the honest definition, we published it: what turnkey actually means.

Link in bio → /learn/what-turnkey-actually-means and /learn/independent-clinic-sovereign-ownership.

#behindthebuild #businesssystems #healthcarebusiness #operations #licensingmodel #businessowners #turnkeybusiness

Compliance: States plainly that Atlas provides no medical services and employs no clinicians; clinical care attributed to 'a separately licensed medical entity' per lexicon. Regulatory line framed as 'confirm with your own counsel in your state' — not a statement of what the law permits. No fee figure. No fabricated humans, and the visual direction explicitly bars fake member data and white-coat imagery.

Four things you'll be told. Four things to check before you believe them.

MYTH: 'Protected territory.'
REALITY: Ask what the word does in the agreement. A geographic promise is a restriction on the seller and a restriction on you. Atlas talks about your market, and we'll show you exactly what is and isn't promised.

MYTH: 'Low fee, we just take a small percentage.'
REALITY: A percentage of revenue is not small. It's permanent, and it follows you to the sale.

MYTH: 'Here's what our partners make.'
REALITY: In the US, earnings claims sit inside franchise disclosure law. If someone shows you income numbers without a Franchise Disclosure Document, the numbers are not the reassurance — they're the red flag. We publish none, ever, by design.

MYTH: 'Turnkey, fully done for you.'
REALITY: Ask what is delivered, on what date, in whose name, and what happens on day 91.

None of the above is legal advice. It's a list of questions for your own counsel.

Link in bio → /learn/evaluating-business-opportunities-questions, /learn/franchise-vs-license and /learn/due-diligence-checklist.

#duediligence #businessopportunity #franchisevslicense #businessownership #redflags #investorquestions #dealstructure

Compliance: 'Territory' used ONLY in the contrast-with-franchise sense the ruling permits; Atlas geography is 'your market'. No competitor named or visually implied — designer must not blur or pixelate a real logo, which identifies as surely as naming. Earnings-claim myth states the FDD principle without asserting what the law requires of any specific party, and closes with an explicit not-legal-advice line. No income figures appear even as examples.

If your supply plan depends on compounded product, put these four dates on a wall.

· December 2024 — FDA removed tirzepatide from the shortage list; compounders were expected to cease by March 2025.
· February 21, 2025 — FDA declared the injectable semaglutide shortage resolved. 503A enforcement discretion ended April 22, 2025; 503B, May 22, 2025.
· September 2025 — FDA issued more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide over statements it deemed false or misleading.
· April 30, 2026 — FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need and expressly rejecting affordability and insurance access as constituting clinical need. Comment period extended; comments were due July 30, 2026.

Sources: FDA; Federal Register docket notice, June 26, 2026; Alston & Bird advisory; IQVIA.

FDA also states that a compounded product with the same active ingredient is not the drug FDA reviewed and approved, and that FDA does not evaluate specific compounded products for safety, effectiveness, manufacturing quality or consistency.

We're not telling you what to source. We're telling you that supply durability is a diligence question with a date on it, and that any answer given to you should survive being checked against the docket.

Link in bio → /learn/how-supplement-supply-chains-work and /learn/due-diligence-checklist.

#fda #regulatoryrisk #supplychain #duediligence #healthcarebusiness #compliance #businessresearch

Compliance: Every item VERIFIED with its date, as the fact base requires for the 503B proposal. No efficacy or safety claim made by Atlas — the safety-relevant language is quoted FDA text with attribution. No competitor or compounder named. Frames as a diligence question, not as guidance on what to source; no legal advice. No product imagery, avoiding any implied efficacy claim.

The question that decides your structure isn't 'what will this cost.' It's 'who is allowed to own the clinical side.'

CAROUSEL SCRIPT (5 slides)

Slide 1 — Corporate practice of medicine.
Slide 2 — It's a body of state-level rules barring unlicensed persons and corporations from owning or controlling a medical practice, or employing physicians for clinical care. The stated purpose is preserving independent medical judgment. (Milbank Memorial Fund issue brief, April 28, 2025.)
Slide 3 — The rules vary by state. We're not going to give you a count of how many states have them — the counts circulating online don't survive checking, and the Milbank brief itself declines to state one.
Slide 4 — The standard response is separation: a clinician-owned professional entity for clinical care, a management services organisation for non-clinical functions. Enforcement risk turns on how much control the MSO exercises over clinical operations and professional judgment.
Slide 5 — Direction of travel in 2025 was tightening. Massachusetts enacted MSO ownership transparency requirements; CPOM-strengthening bills were introduced in Oregon, Washington and California.

Atlas provides no medical services and employs no clinicians. Clinical care sits with a separately licensed medical entity. What that means for you, in your state, is a question for your own counsel — and it should be one of the first calls you make, not one of the last.

Link in bio → /learn/compliance-basics-for-wellness-businesses and /learn/independent-clinic-sovereign-ownership.

#healthcarelaw #cpom #businessstructure #healthcarebusiness #compliance #duediligence #msostructure

Compliance: CPOM described as varying by state with NO count given, per the DO-NOT-USE ruling on the '33 states' figure; the refusal is made visible rather than hidden. Milbank cited with date. Every regulatory statement is framed as what to verify with your own counsel in your state — no statement of what the law permits for the reader. Atlas's no-clinicians position restated. Visual direction bars the shaded map that would smuggle in a count.

Telehealth doesn't make the number smaller. It moves the number.

A telehealth-first or hybrid model changes what you're paying for, not necessarily how much:

Lines it avoids — build-out and renovation, clinical equipment.
Lines it adds — multi-state licensure, technology.

That's a statement about composition. We're not putting a total on it, because there isn't an honest one to put. The startup ranges that circulate in this category get attributed to a major practice-management survey that we could not trace to that source, so we label them what they are: unverified secondary aggregation, not a benchmark.

Two costs that are checkable:
· DEA practitioner registration: $888 per three-year term (21 CFR 1301.13).
· Medical liability premiums have risen for a seventh consecutive year — the share of premiums increasing year over year went from 13.7% in 2018 to nearly 40% in 2025, the highest since 2005 (AMA Policy Research Perspectives, May 4, 2026, using Medical Liability Monitor data).

On licensure: medical practice is generally deemed to occur where the patient is located, so a clinician typically must be licensed in the patient's state. The Interstate Medical Licensure Compact covered up to 43 member states as of March 2026.

All of it is jurisdiction-specific. Verify yours with your own counsel.

Link in bio → /learn/telehealth-vs-in-clinic-metabolic-care and /learn/unit-economics-metabolic-care.

#telehealth #healthcarebusiness #startupcosts #duediligence #businessplanning #compliance #practicemanagement

Compliance: Cost composition labelled as composition, not magnitude, per the INFERENCE in the fact base; the untraceable startup range is named and refused rather than repeated, and MGMA is not cited. $888 (21 CFR 1301.13) and the AMA/MLM premium trend are VERIFIED and dated. The Miami-Dade premium outlier is deliberately omitted here to avoid it reading as typical. No revenue, margin or payback figure — the empty ledger column is intentional and the designer must not fill it. Licensure framed as verify-with-counsel.

You will not find our price on this page. That's not coyness. It's the same discipline that keeps income numbers off it.

Here's the whole reasoning, out loud.

A number on a graphic is a number without an agreement attached. It gets screenshotted, it gets quoted back six months later, and it gets compared against offers that are not structurally the same thing. So the license fee goes on the fit call, with the person who is looking at what's actually included and what's actually promised. The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own.

What we will say publicly, and will keep saying:
· One-time license fee.
· 0% of revenue.
· No ongoing partner fees.

And the thing we get asked about most: no, we don't publish what partners make. Not a range, not a case study, not an illustrative example. In the US, earnings claims live inside franchise disclosure law, and a number offered outside that framework is not evidence — it's exposure, for us and for you. The restraint is the disclosure.

If that reads as less exciting than the alternative, good. You're going to be reading agreements for a living soon.

— reserved. Fills only with a named, consented Atlas partner speaking about the build process, with written release on file. No composites, no stand-ins, no results language.

Link in bio → /learn/franchise-vs-license and /learn/evaluating-business-opportunities-questions. Fit call when you're ready for the number.

#businessownership #licensingmodel #transparency #duediligence #healthcarebusiness #entrepreneurship #dealstructure

Compliance: No fee figure; The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. token in place. No earnings claim, and the post makes the absence the message rather than hinting at magnitude — no 'less than you'd think', no range, no comparison anchor. carries its fill requirement inline: named, consented partner, written release, build-process language only, never results. No competitor named. Designer must not add a strikethrough number or a blurred figure behind the redaction bar — a blur implies a magnitude.

Everyone watched the drug. Almost nobody watched the checkout counter.

(0-2s) VO: "Everyone watched the drug. Almost nobody watched the checkout counter."
[TEXT: THE PART NOBODY COVERED]

(2-8s) VO: "KFF polled US adults at the end of 2025. Eighteen percent say they've ever used a GLP-1. Twelve percent are using one right now — up six points since May 2024."
[TEXT: 18% ever used / 12% currently — KFF, Oct 27–Nov 2 2025]

(8-22s) VO: "Here's the line that should stop an operator cold. Twenty-seven percent of users had insurance — and paid the entire cost themselves anyway. Fifty-six percent said affording it was difficult. Fourteen percent stopped because of cost."
[TEXT: 27% HAD INSURANCE. PAID 100% ANYWAY.]

(22-38s) VO: "That's not a supply story. That's a coverage story. And coverage stories don't resolve in a quarter — they sit in statute and in benefit design. So a whole layer of this category runs cash-pay, by structure, not by trend."
[TEXT: CASH-PAY BY STRUCTURE, NOT BY TREND]

(38-50s) VO: "I'm not going to tell you what that's worth to anyone. I'm telling you where the demand actually comes from — and that's the only part you can verify before you commit a dollar."
[TEXT: VERIFY THE MECHANISM, NOT THE HYPE]

Full market read is on the site — /learn/metabolic-wellness-market-overview. Link in bio.

#glp1 #healthcarebusiness #cashpay #marketresearch #entrepreneurship

Compliance: All figures VERIFIED from KFF Health Tracking Poll (fielded Oct 27–Nov 2, 2025). Closing line explicitly refuses a value/earnings statement. No price, no income or ROI claim, no efficacy claim, no named person, no competitor. Lexicon: no 'patient' language used for Atlas enrollees; script never bridges market data to buyer results.

"Insurance doesn't cover it" isn't the problem with this category. It's the category.

(0-2s) VO: "'Insurance doesn't cover it' isn't the problem with this category. It's the category."
[TEXT: THE EXCLUSION IS THE MARKET]

(2-14s) VO: "Medicare Part D has been barred by statute from covering drugs used for weight loss since the program was written in 2003. Not a policy preference. Statute."
[TEXT: MEDICARE MODERNIZATION ACT, 2003 — STATUTORY EXCLUSION]

(14-30s) VO: "The workarounds are temporary and voluntary. The Medicare GLP-1 Bridge runs July 1st 2026 through December 2027 at a fifty-dollar monthly copay — and those copays don't count toward Part D deductibles or out-of-pocket maximums. The BALANCE model started for Medicaid in May 2026 and was delayed indefinitely for Part D after plan participation fell short of an eighty percent threshold."
[TEXT: TEMPORARY. VOLUNTARY. DATE-STAMPED.]

(30-44s) VO: "Employers? KFF's 2025 survey: sixteen percent of firms with 200 to 999 workers cover GLP-1s used primarily for weight loss. Thirty percent at one to five thousand. Forty-three percent at five thousand-plus."
[TEXT: 16% / 30% / 43% — KFF EHBS 2025]

(44-55s) VO: "Read that as an operator: the mid-market employee is mostly uncovered. That's who's paying out of pocket. Everything else about this business is downstream of that sentence."
[TEXT: EVERYTHING IS DOWNSTREAM OF WHO PAYS]

We wrote the long version: /learn/cash-pay-metabolic-health-program-structure. Link in bio.

#healthpolicy #glp1 #healthcarebusiness #medicare #businessstrategy

Compliance: All coverage facts VERIFIED (KFF Medicare analysis; KFF 2025 Employer Health Benefits Survey, fielded Jan–Jul 2025, 1,862 firms). Coverage percentages are market data, never converted into demand volume or operator revenue. The closing INFERENCE ('mid-market employee is mostly uncovered') is a restatement of the cited coverage data, not a forecast. No price, no income claim, no legal advice — nothing here tells a viewer what the law permits them to do.

A royalty isn't a share of your profit. Read that again.

(0-2s) VO: "A royalty isn't a share of your profit. Read that again."
[TEXT: ROYALTY ≠ PROFIT SHARE]

(2-16s) VO: "In most franchise agreements the royalty is calculated on gross revenue. Money in the door. Before rent. Before payroll. Before product cost. Before the card processing fee."
[TEXT: GROSS = BEFORE EVERYTHING]

(16-32s) VO: "Which means the percentage doesn't care what kind of month you had. Slow month, royalty. Bad month, royalty. Month you personally covered payroll, still royalty. And it doesn't end — it's the whole term of the agreement."
[TEXT: THE PERCENTAGE DOESN'T CARE]

(32-46s) VO: "I'm deliberately not putting numbers on screen, because the second I do I'm making up your business for you. Go read Item 6 of any real disclosure document instead. Item 6 is where the recurring fees live, and it's the page most people skim."
[TEXT: READ ITEM 6. TWICE.]

(46-58s) VO: "Atlas is a license, not a franchise. One-time license fee, zero percent of revenue, no ongoing partner fees. I'm not asking you to take that on faith — I'm asking you to go compare the fee structures line by line."
[TEXT: LICENSE. 0% OF REVENUE. COMPARE IT YOURSELF.]

Two explainers, link in bio: /learn/what-a-royalty-really-costs and /learn/fdd-item-6-gross-royalty-explained.

#franchise #duediligence #businessowner #licensing #smallbusinessfinance

Compliance: Describes royalty MECHANICS only — no percentages, no dollar figures, no worked example, therefore no earnings claim and no implied P&L. 'Franchise' and 'territory'-adjacent language appears only as a contrast to what Atlas offers, which the lexicon permits. Atlas terms stated (one-time license fee, 0% of revenue, no ongoing fees) are offer terms, not income claims. Price withheld: The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. belongs anywhere the actual fee is named. No competitor named. No legal advice — viewer is told to read the document, not what it means for them.

Three reasons I'd talk you out of this business before I'd talk you into it.

(0-2s) VO: "Three reasons I'd talk you out of this business before I'd talk you into it."
[TEXT: REASONS NOT TO DO THIS]

(2-16s) VO: "One. Corporate practice of medicine. Most states have rules that stop a non-clinician or a corporation from owning or controlling a medical practice. The usual answer is separating a clinician-owned entity from a management company — and enforcement risk turns on how much control that management company actually exercises. In 2025 the movement was toward tightening, not loosening."
[TEXT: 1. CPOM — VARIES BY STATE, TIGHTENING]

(16-30s) VO: "Two. Licensure follows the member, not your office. Medicine is generally deemed to happen where the person is located. The Interstate Compact covered up to forty-three states as of March 2026 — that's a pathway, not a free pass."
[TEXT: 2. LICENSED WHERE THEY ARE, NOT WHERE YOU ARE]

(30-44s) VO: "Three. The supply rules move. FDA has been actively reshaping what can be compounded, with dated actions through 2025 and a live proposal in 2026. Anyone selling you a model that assumes today's rules hold forever is selling you a snapshot."
[TEXT: 3. THE RULES MOVE. PLAN FOR THAT.]

(44-56s) VO: "None of that is legal advice and I'm not your lawyer. It's the list of things to hand your own counsel, in your own state, before you sign anything."
[TEXT: TAKE THIS LIST TO YOUR OWN COUNSEL]

The checklist version lives at /learn/due-diligence-checklist and /learn/compliance-basics-for-wellness-businesses. Link in bio.

#duediligence #healthcarecompliance #telehealth #businessrisk #entrepreneurship

Compliance: CPOM and licensure facts VERIFIED (Milbank issue brief, April 28 2025; FSMB/IMLC via Pullman & Comley, March 2026). Deliberately gives NO state count for CPOM — that figure is flagged unverified in the fact base. Framed throughout as 'what to verify with your own counsel in your state', with an explicit non-advice line, satisfying the no-legal-advice rule. Uses 'member' per lexicon. No price, no income claim, no competitor, no efficacy claim.

If your business model depends on compounded GLP-1s, put this date in your calendar.

(0-2s) VO: "If your business model depends on compounded GLP-1s, put these dates in your calendar."
[TEXT: THE DATES NOBODY PUTS IN THE PITCH DECK]

(2-16s) VO: "December 2024 — FDA removes tirzepatide from the shortage list. February 21st 2025 — the injectable semaglutide shortage is declared resolved. Enforcement discretion ends April 22nd for 503A pharmacies, May 22nd for 503B outsourcing facilities."
[TEXT: DEC 2024 → FEB 21 2025 → APR 22 → MAY 22]

(16-30s) VO: "September 2025 — FDA issues more than fifty warning letters over statements it deemed false or misleading. April 30th 2026 — FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, and expressly rejects affordability and insurance access as constituting clinical need. Comments closed July 30th 2026."
[TEXT: APRIL 30, 2026 — LIVE PROPOSAL]

(30-44s) VO: "And FDA's own position is that a compounded product with the same active ingredient is not the drug FDA reviewed and approved — the agency doesn't evaluate those products for quality or consistency."
[TEXT: FDA: NOT THE DRUG FDA APPROVED]

(44-58s) VO: "I'm not telling you what to stock. I'm telling you that 'it's working right now' is not a durability answer, and any build you buy should survive the rules changing again."
[TEXT: BUILD FOR THE RULE CHANGE]

Supply-chain breakdown at /learn/how-supplement-supply-chains-work. Link in bio.

#fda #glp1 #supplychain #healthcarebusiness #riskmanagement

Compliance: Every date VERIFIED (Alston & Bird; IQVIA Oct 2025; FDA drug alerts page; Federal Register docket notice June 26 2026). Presents the 503B bulks proposal WITH its dates as the fact base requires. Quotes FDA's own characterization rather than making any independent safety or efficacy claim. No recommendation about what to dispense or use — no medical advice. No price, no income claim, no competitor, no invented person.

The most expensive way into this category is to treat it as one more line on your menu.

(0-2s) VO: "The most expensive way into this category is to treat it as one more line on your menu."
[TEXT: MENU ITEM vs PROGRAM]

(2-16s) VO: "Here's the pattern. An existing aesthetics or wellness business adds metabolic to the service list. New sign, new intake form, same operating system. The clinical side keeps seeing its own patients the way it always has, and the metabolic side never becomes its own thing."
[TEXT: NEW SIGN. SAME OPERATING SYSTEM.]

(16-32s) VO: "A menu item is transactional. Somebody buys, somebody leaves, you go buy the next lead. A program has a defined arc — enrollment, structured touchpoints, a reason for a member to still be a member in month six. Those are different businesses that happen to share a hallway."
[TEXT: TRANSACTION vs ENROLLED MEMBER]

(32-46s) VO: "And the structural piece people discover late: clinical care has to sit inside a separately licensed medical entity, with real separation between clinical judgment and the business functions around it. Retrofitting that after you've launched is more expensive than designing it in."
[TEXT: STRUCTURE FIRST. NOT AFTER.]

(46-58s) VO: "I'm not naming anybody and I'm not going to pretend I have a case study for you. This is the shape of the mistake, and it's avoidable on a whiteboard for free."
[TEXT: FIX IT ON A WHITEBOARD, NOT IN MONTH NINE]

Integration write-up: /learn/medspa-weight-loss-program-integration and /learn/functional-medicine-high-ticket-enrollment. Link in bio.

#medspa #wellnessbusiness #businessmodel #retention #healthcarebusiness

Compliance: NO fabricated human, no composite owner, no invented case study — the script says so out loud. The 'pattern' described is INFERENCE about business structure, framed as a shape rather than a documented event, with no statistics attached. Lexicon respected: the existing practice's clinical side has 'patients', Atlas program enrollees are 'members'; 'program' not protocol; 'a separately licensed medical entity' not our clinicians. If real consented proof is later added here, it goes in and must be a named, consented partner speaking for themselves — no composites. No price, no income claim, no efficacy claim, no legal advice.

Ask one question before you sign anything: when this ends, who keeps the list?

(0-2s) VO: "One question before you sign anything: when this ends, who keeps the list?"
[TEXT: WHO KEEPS THE LIST?]

(2-16s) VO: "Not the equipment. Not the sign. The member list, the brand you spent years building recognition for, the domain, the phone number, the data."
[TEXT: LIST. BRAND. DOMAIN. NUMBER. DATA.]

(16-32s) VO: "In a lot of agreements, the answer is not you. You operate under somebody else's brand, you build the goodwill, and at renewal or termination the thing you built recognition for goes back in their drawer. That's not a scandal — it's written down. People just don't read that far."
[TEXT: IT'S NOT HIDDEN. IT'S UNREAD.]

(32-46s) VO: "A license is a different shape. You own the brand you build. You own the relationship with your members. The build gets handed to you and it stays yours."
[TEXT: LICENSE: THE BRAND IS YOURS]

(46-58s) VO: "Don't take my framing for it. Take the exit clause of whatever's in front of you, and read the termination section before you read the pitch."
[TEXT: READ THE TERMINATION SECTION FIRST]

Longer version at /learn/owning-your-brand, /learn/franchise-vs-license and /learn/independent-clinic-sovereign-ownership. Link in bio.

#duediligence #franchise #brandownership #licensing #businessowner

Compliance: No competitor named or implied by description of any identifiable company — the comparison is to franchise agreements as a category, which the lexicon permits as contrast. No income claim, no price (The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. if a fee is ever named on screen), no fabricated person, no guarantee. 'Member' and 'build' used per lexicon; 'license fee' never described as an investment. Contract commentary is generic and viewer is directed to read their own document — not legal advice.

People ask why the price isn't on the website. Here's the actual answer.

(0-2s) VO: "People ask why the price isn't on the website. Here's the actual answer."
[TEXT: WHY THERE'S NO NUMBER ON THE SITE]

(2-14s) VO: "A number on a landing page does one job: it filters for people shopping on price. That's the wrong filter for something that takes months to build and years to operate."
[TEXT: A PRICE TAG FILTERS FOR THE WRONG BUYER]

(14-30s) VO: "The second reason is more important. The moment a company publishes a fee, the next thing it wants to publish is what you'd make back. And nobody in this category can responsibly publish that. We have no franchise disclosure document, which means any earnings figure — even a friendly hypothetical — is a claim we're not entitled to make."
[TEXT: NO FDD = NO EARNINGS FIGURES. EVER.]

(30-44s) VO: "So we don't do the number-and-a-payback-chart routine. There's a fee schedule, it's specific, and it comes out on a fit call where I can answer follow-up questions instead of leaving you with a headline."
[TEXT: The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own.]

(44-56s) VO: "If a company shows you a fee and a return in the same breath, that's not transparency. That's the part you're supposed to check."
[TEXT: CHECK THE PART THAT LOOKS LIKE TRANSPARENCY]

Start with /learn/evaluating-business-opportunities-questions and /learn/medical-wellness-franchise-cost-comparison. Fit call link in bio.

#duediligence #businessopportunity #franchise #transparency #entrepreneurship

Compliance: No price, no range, no hint — The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. token used at the point where a figure would naturally appear, and left for the build layer. Explicitly refuses earnings claims and states the no-FDD reason, which is the company's own doctrine. No competitor named ('a company' is generic). No guarantee, no invented person, no market statistic used, so no sourcing burden. Lexicon: 'license fee', 'build', 'partner' framing preserved.

You've seen three different market sizes for this category. All three are real. That's the problem.

(0-2s) VO: "You've seen three different market sizes for this category. All three are real. That's the problem."
[TEXT: SAME MARKET. THREE NUMBERS.]

(2-16s) VO: "Morgan Stanley Research projects global GLP-1 sales across diabetes and obesity at roughly one hundred ninety billion by 2035 — more than double 2025."
[TEXT: ~$190B BY 2035 — MORGAN STANLEY RESEARCH]

(16-28s) VO: "Goldman Sachs Research puts the global anti-obesity drug market near ninety-five billion by 2030 — and that's a revision down, from about one-thirty."
[TEXT: ~$95B BY 2030 — REVISED DOWN FROM ~$130B]

(28-40s) VO: "Grand View Research has the narrower GLP-1 weight-loss segment at about forty-eight point eight billion by 2030, eighteen and a half percent compound growth."
[TEXT: ~$48.8B BY 2030 — GRAND VIEW]

(40-52s) VO: "The gap isn't one of them lying. It's definitional — class-wide versus indication-specific, different end years. If a deck quotes you the biggest one with no definition attached, that tells you something about the deck."
[TEXT: DEFINITIONAL, NOT DISHONEST]

(52-60s) VO: "And none of these tell you a thing about what any single operator does. They size a category. That's all they do."
[TEXT: CATEGORY SIZE ≠ ANYONE'S RESULTS]

Our market read, with the definitions attached: /learn/metabolic-wellness-market-overview. Link in bio.

#marketresearch #glp1 #duediligence #investing101 #healthcareindustry

Compliance: All three figures VERIFIED (Morgan Stanley Research; Goldman Sachs Research, using the downward revision per fact-base instruction; Grand View Research). Deliberately omits the unverified $132B 2025 category-sales figure, per-product 2025 sales, and the unattributable 30% penetration assumption. Closing line explicitly severs market data from any implied personal earnings, satisfying the no-bridging rule. No price, no competitor, no invented person.

"Go telehealth, it's cheaper." It isn't cheaper. It's different lines.

(0-2s) VO: "'Go telehealth, it's cheaper.' It isn't cheaper. It's different lines."
[TEXT: NOT CHEAPER. DIFFERENT.]

(2-16s) VO: "A brick-and-mortar build carries lines a telehealth-first model doesn't: build-out, clinical equipment, the physical footprint. That's real and it's a lot."
[TEXT: WHAT YOU DROP: BUILD-OUT, EQUIPMENT, FOOTPRINT]

(16-32s) VO: "But go telehealth-first and you pick up lines the clinic doesn't have. Multi-state licensure — because medicine is generally deemed to happen where the member is, not where you are. The Interstate Compact covered up to forty-three states as of March 2026, which is a pathway, not a shortcut. Plus a technology stack you now depend on completely."
[TEXT: WHAT YOU PICK UP: LICENSURE + TECH STACK]

(32-46s) VO: "And some costs don't care which model you pick. DEA practitioner registration is eight hundred eighty-eight dollars per three-year term — that's in the CFR, go look. Medical liability premiums have risen seven years running; the share of premiums going up year over year went from under fourteen percent in 2018 to nearly forty percent in 2025."
[TEXT: $888 / 3 YEARS — 21 CFR 1301.13]

(46-58s) VO: "So the honest framing isn't cheaper or more expensive. It's: which set of costs do you actually want to own?"
[TEXT: WHICH COSTS DO YOU WANT TO OWN?]

Side-by-side at /learn/telehealth-vs-in-clinic-metabolic-care and /learn/clinic-vs-digital-model. Link in bio.

#telehealth #healthcarebusiness #unitEconomics #businessplanning #duediligence

Compliance: Cost data only — no revenue, margin, payback or break-even figure appears, and no cost figure is combined with another to imply results. DEA fee VERIFIED (21 CFR 1301.13); liability premium trend VERIFIED (AMA Policy Research Perspectives, May 4 2026, using Medical Liability Monitor data). Deliberately omits the widely repeated $70k–$500k startup range and the Miami-Dade outlier premium — the first is INFERENCE with an untraceable MGMA attribution, the second is an outlier that reads as typical in a short video. The cost-composition point is stated as composition, not magnitude, per the fact base. Lexicon: 'member', 'build'. No price, no income claim, no legal advice, no competitor, no invented person.